Changes in Beneficial Ownership · 4
Twist Bioscience Corporation
TWSTNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
marketforms-74024.xml
Filing details
- Report period
- 2026-09-17
- Issuer
- Twist Bioscience Corp
- Issuer CIK
- 0001581280
- Trading symbol
- TWST
- Rule 10b5-1 indication
- Checked
Reporting owner 1
- Name
- Leproust Emily M.
- Reporting owner CIK
- 0001753655
- Relationship
- Director · Officer
- Officer title
- Chief Executive Officer
- Address
- C/O TWIST BIOSCIENCE CORPORATION, 681 GATEWAY BLVD., SOUTH SAN FRANCISCO, CA, 94080
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-09-17 | M · Form 4[F1] | 133,269 | A | 26.66 | 901,696 | D |
| Common Stock | 2026-09-17 | M · Form 4[F1] | 75,439 | A | 8.82 | 977,135 | D |
| Common Stock | 2026-09-17 | S · Form 4[F1] | 2,440 | D | 151.4613[F2] | 974,695 | D |
| Common Stock | 2026-09-17 | S · Form 4[F1] | 6,644 | D | 152.2112[F3] | 968,051 | D |
| Common Stock | 2026-09-17 | S · Form 4[F1] | 3,399 | D | 153.4031[F4] | 964,652 | D |
| Common Stock | 2026-09-17 | S · Form 4[F1] | 4,175 | D | 154.1703[F5] | 960,477 | D |
| Common Stock | 2026-09-17 | S · Form 4[F1] | 13,378 | D | 155.4568[F6] | 947,099 | D |
| Common Stock | 2026-09-17 | S · Form 4[F1] | 9,097 | D | 156.4674[F7] | 938,002 | D |
| Common Stock | 2026-09-17 | S · Form 4[F1] | 32,260 | D | 157.4860[F8] | 905,742 | D |
| Common Stock | 2026-09-17 | S · Form 4[F1] | 232,173 | D | 158.0876[F9] | 673,569 | D |
| Common Stock | 2026-09-17 | S · Form 4[F1] | 23,884 | D | 159.5315[F10] | 649,685 | D |
| Common Stock | 2026-09-17 | S · Form 4[F1] | 14,493 | D | 160.4392[F11] | 635,192 | D |
| Common Stock | 2026-09-17 | S · Form 4[F1] | 11,169 | D | 161.4930[F12] | 624,023 | D |
| Common Stock | 2026-09-17 | S · Form 4[F1] | 2,565 | D | 162.3136[F13] | 621,458 | D |
| Common Stock | 2026-09-17 | S · Form 4[F1] | 869 | D | 163.3926[F14] | 620,589 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- D
- Direct
- S · Form 4
- Sale on the market or privately
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy) | 8.82 | 2026-09-17 | M · Form 4 | 75,439 | D | 0 | [F18] | 2027-09-28 | Common Stock | 75,439 | 0 | D |
| Employee Stock Option (right to buy) | 26.66 | 2026-09-17 | M · Form 4 | 133,269 | D | 0 | [F19] | 2028-11-18 | Common Stock | 133,269 | 0 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- D
- Direct
Derivative holdings
| Security | Conversion / exercise price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Amount owned | Ownership |
|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy) | 5.95 | [F15] | 2025-09-28 | Common Stock | 0 | 0 | D |
| Employee Stock Option (right to buy) | 23.33 | [F16] | 2029-10-23 | Common Stock | 131,290 | 131,290 | D |
| Employee Stock Option (right to buy) | 67.85 | 2022-12-19 | 2030-08-31 | Common Stock | 64,950 | 64,950[F17] | D |
Table key
- D
- Direct
Footnotes
- F1
- The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026.↩ 1↩ 2↩ 3↩ 4↩ 5↩ 6↩ 7↩ 8↩ 9↩ 10↩ 11↩ 12↩ 13↩ 14↩ 15
- F2
- Represents the weighted average sales price per share. The shares sold at prices ranging from $150.77 to 151.77 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.↩ 1
- F3
- Represents the weighted average sales price per share. The shares sold at prices ranging from $151.78 to $152.71 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.↩ 1
- F4
- Represents the weighted average sales price per share. The shares sold at prices ranging from $152.87 to $153.85 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.↩ 1
- F5
- Represents the weighted average sales price per share. The shares sold at prices ranging from $153.88 to $154.84 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.↩ 1
- F6
- Represents the weighted average sales price per share. The shares sold at prices ranging from $154.9 to $155.9 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.↩ 1
- F7
- Represents the weighted average sales price per share. The shares sold at prices ranging from $155.92 to $156.91 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.↩ 1
- F8
- Represents the weighted average sales price per share. The shares sold at prices ranging from $156.96 to $157.96 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.↩ 1
- F9
- Represents the weighted average sales price per share. The shares sold at prices ranging from $157.97 to $158.96 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.↩ 1
- F10
- Represents the weighted average sales price per share. The shares sold at prices ranging from $158.99 to $159.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.↩ 1
- F11
- Represents the weighted average sales price per share. The shares sold at prices ranging from $160.00 to $160.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.↩ 1
- F12
- Represents the weighted average sales price per share. The shares sold at prices ranging from $161.00 to $161.97 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.↩ 1
- F13
- Represents the weighted average sales price per share. The shares sold at prices ranging from $162.02 to $163 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.↩ 1
- F14
- Represents the weighted average sales price per share. The shares sold at prices ranging from $163.03 to $163.6 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.↩ 1
- F15
- The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.↩ 1
- F16
- 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.↩ 1
- F17
- Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.↩ 1
- F18
- The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.↩ 1
- F19
- The option is immediately exercisable. 20% of the shares subject to the option vested and became exercisable on October 31, 2019 and 1/60th of the shares subject to the option vested and became exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.↩ 1
Signature 1
- Signed
- /s/ Kendra Fox, as Attorney-in-Fact for Emily M. Leproust
- Date
- 2026-09-21
Company context
At Twist Bioscience, our customizable solutions across the biological continuum raise the bar in diagnostics, therapeutics, industrial, agriculture and research markets. We drive innovation with confidence, without compromise. Whether delivering oligos, genes, proteins, libraries, characterization data, antibody discovery solutions, or NGS workflow tools, our scientific expertise and exceptional customer experience help navigate complex challenges, all with precision and at the scale and speed customers require. By enhancing R&D efficiency at every turn, we give scientists more shots on goal - more experiments, more iterations, more chances for remarkable discoveries.
Current securities
Recent company filings
- Results of Operations and Financial ConditionNov 12, 2026
- SCHEDULE 13G/A - filed by Artisan Partners Limited Partnership regarding Twist Bioscience CorpNov 12, 2026
- SCHEDULE 13G - filed by STATE STREET CORP regarding Twist Bioscience CorpNov 10, 2026
- SCHEDULE 13G/A - filed by FMR LLC regarding Twist Bioscience CorpNov 5, 2026
- 144 filingSep 21, 2026